Postoperative mortality in parathyroid surgery in Sweden during five decades: improved outcome despite older patients

S Norenstedt1, A Ekbom2, I Brandt2, J Zedenius1 and I-L Nilsson1
1Endocrine Surgery Unit, Department of Molecular Medicine and Surgery and 2Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, SE 171 76 Stockholm, Sweden

Abstract

Objective: Primary hyperparathyroidism (pHPT) is a common endocrine disorder. In Europe, pHPT has been associated with premature death in cardiovascular disorders. Our question was whether the risk of postoperative death has been affected by the increased proportion of elderly patients referred for parathyroid surgery.

Methods: The nationwide Cancer Registry and Causes-of-Death Registry were used to analyze mortality among 14 635 Swedish patients subjected to parathyroid adenomectomy (PTx) during 1961–2004. Standard mortality ratios (SMR) and the 95% confidence intervals (CI) were calculated with the entire Swedish population as control, standardized for age, gender and calendar year.

Results: The observation period was more than 166 000 person-years. The overall perioperative (30-day) mortality rate was 1.3% (185/14 635; SMR 7.9; CI 6.82–9.15); 1.1% for women (132/11 500; SMR 7.56; CI 6.32–8.96), and 1.7% for men (53/3135; SMR 9.01; CI 6.75–11.78). Cardiovascular disorder was the dominant cause of death in both sexes and in all the investigated age groups (age 15–54 years; SMR 29.0; CI 9.42–67.71, age 55–74 years; SMR 6.12; CI 3.96–9.03, age 75 years: SMR 5.26; CI 3.74–7.19). The SMR decreased over the calendar year period notwithstanding a rising proportion of elderly individuals. In the most recent period, 1997–2004, the perioperative mortality rate was only 0.5%, which represents a normalization of the excess mortality risk during the first post-PTx year (SMR 1.17; CI 0.92–1.46).

Conclusion: PTx is a safe procedure, regardless of patient age. Today, the perioperative mortality risk is not a reason for excluding elderly patients from parathyroid surgery.

Introduction

Primary hyperparathyroidism (pHPT) is a common endocrine disorder, often detected by routine measurement of serum calcium levels. The clinical profile has shifted from a disease with pronounced renal, skeletal, and mental symptoms to a more diffuse symptomatology. Today, pHPT appears to be associated with an overrepresentation of cardiovascular dysfunction, diabetes mellitus, and dyslipidemia (1). PHPT, at least in Europe, has been associated with premature death, especially in cardiovascular disorders (2–4). The risk of dying applies to both sexes and all age groups and normalizes with time after parathyroid adenomectomy (PTx), while hypercalcemia treated conservatively still carries a slightly elevated risk of premature death (4, 5).

The only definite treatment of pHPT is parathyroid surgery. Today, better techniques for the preoperative localization of a parathyroid adenoma with ultrasonography and/or parathyroid scintigraphy permit a less invasive surgical approach. Since life expectancy has risen and the threshold for referral of pHPT patients for PTx has been lowered, the proportion of elderly patients has increased. Data on morbidity and mortality after PTx in elderly people are conflicting. Some authors report quite high-risk estimates, others claim a benefit of PTx for all age groups (6–10). The aim of this study was to analyze all cause mortality within 30 days and 1 year after PTx.

Materials and methods

A cohort of 14 635 Swedish patients (11 500 women) subjected to PTx during the period from January 1961 to December 2004 was generated from the Swedish National Cancer Registry (Table 1). Requisites for patient inclusion were histological verification of the adenoma at routine microscopic examination by a qualified pathologist and clinical features supporting the diagnosis of parathyroid adenoma. Since 1958, all malignant and a few benign tumors, including parathyroid adenomas, have to be reported to the Cancer Registry, both by the treating physician and by
the pathologist who establishes the diagnosis. Only patients with a single adenoma were included, not those with parathyroid hyperplasia. The information in the Cancer Registry includes date of diagnosis, type of tumor and diagnosis coded according to the International Classification of Diseases (ICD), version 7. The Cancer Registry has been validated and underreporting is 2–3% (11).

Mortality in the cohort was derived from the National Causes-of-Death Registry from 1961 until the end of 2004. This register includes all deaths from 1952 onwards among registered Swedish residents. It also contains the underlying and contributory causes of death from the physician’s death certificate in accordance with ICD-7, 8, and 9, and the date of death. The accuracy of the data concerning disease groups has been considered reliable (12).

Matching between registers was achieved by means of the individual National Registration Number that is allocated to every Swedish resident. The person-year at risk was counted from the date of entry into the cohort until death, emigration or the end of the observation period, i.e., 31 December, 2004. Standard mortality ratios (SMR) were calculated with the entire Swedish population as control, standardized for age, gender, and calendar year. SMR are calculated as the ratio of the observed to the expected number of deaths and used as an indicator of risk. Nationwide statistics from the Causes-of-Death Registry include annual sex- and age-specific mortality rates for different ICD codes. The expected number of deaths in the observed population was calculated by multiplying the number of person-years at risk for each 5-year age group, gender, and calendar year, by the corresponding age, gender, and calendar year-specific mortality rates in the general population. The 95% confidence interval (CI) of SMR was calculated on the assumption that the number of deaths in various categories follows the Poisson distribution. Various stratification studies have been conducted, which include age and calendar year at entry, the duration of follow-up, attained age, gender, and various combinations.

**Results**

Of the 14,635 pHPT patients in the cohort, 79% were women. The observation time was more than 166,000 person-years. The mean age of the patients increased from 53 years during 1961–1971 to 64 years during 1992–2004 \( (p < 0.0001) \). Nearly, 3000 of the pHPT patients were 75 years of age or more at the time of PTx and this age group constituted more than a quarter of the cases in the most recent period (1997–2004). During the entire period, 185 patients died within 1 month and 365 during the next 11 months after PTx (Table 2). The overall 30-day mortality after PTx was 1.3% \( (185/14,635; \text{SMR 7.92; CI 6.82–9.15}) \); 1.1% for women \( (132/11,500; \text{SMR 7.56; CI 6.32–8.96}) \), and
1.7% for men (53/3135; SMR 9.01; CI 6.75–11.78). An analysis of the 30-day mortality over time showed a decrease from 4.2% during 1961–1976 to 0.4% during 1997–2004. The mortality during day 31 to day 365 after PTx ceased to be significantly increased from 1987 onwards.

The causes of death within the first month and the following 11 months after PTx are listed in Table 3. The dominant causes of mortality during the first month after PTx were cardiovascular (37%), endocrine (32%), and malignancy-related (17%), demonstrable in both genders and in all the investigated age groups (Tables 4 and 5). Of the patients who died within the first year after PTx, 51% did so from a cardiovascular disorder. The second and third causes in absolute terms were tumors and endocrine disorders (around 15% each). The number of deaths in endocrine disorders decreased from 41 in 1961–1976 to four during the latest time period. (Table 5).

Discussion

The key finding in the study was a decrease in the postoperative mortality risk during the observation period notwithstanding the increasing mean age of individuals subjected to PTx.

The cohort was recruited from the nationwide Swedish Cancer Registry, to which parathyroid adenomas together with all hormone-producing tumors are compulsory reported by the treating physician as well as by the examining pathologist. The material and the study design have some limitations. The cohort represents persons with diagnosed pHPT who underwent PTx in accordance with the prevailing routine. Since many cases are not diagnosed or are not referred for PTx, the cohort cannot be said to represent the entire Swedish pHPT population. Also, the Swedish Cancer Registry from which patients were recruited does not contain any information about parathyroid hyperplasia, which is not reported to the Registry. Consequently, the study does not include some 15% of persons with pHPT. The main limitation of the study is that the registers contain no detail about the degree of hypercalcemia, symptoms, surgical procedure, and postoperative serum calcium levels.

However, the size of the investigated cohort, 14,635 patients subjected to PTx, provides sufficient statistical power for the analysis of postoperative mortality. The registry is well validated. Missing reports of other

<table>
<thead>
<tr>
<th>Disease group (ICD)</th>
<th>First month after PTx</th>
<th>2–12 months after PTx</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>SMR</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>69</td>
<td>5.91</td>
</tr>
<tr>
<td>Endocrine</td>
<td>59</td>
<td>119.20</td>
</tr>
<tr>
<td>Tumor</td>
<td>31</td>
<td>5.02</td>
</tr>
<tr>
<td>Respiratory</td>
<td>9</td>
<td>6.11</td>
</tr>
<tr>
<td>Urogenital</td>
<td>5</td>
<td>16.03</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>5</td>
<td>6.54</td>
</tr>
<tr>
<td>Trauma/violence</td>
<td>4</td>
<td>4.73</td>
</tr>
<tr>
<td>Infectious</td>
<td>1</td>
<td>4.67</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>1</td>
<td>5.75</td>
</tr>
<tr>
<td>Neurological</td>
<td>1</td>
<td>2.77</td>
</tr>
<tr>
<td>Hematological</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Psychiatric</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Total number</td>
<td>185</td>
<td>7.92</td>
</tr>
</tbody>
</table>

ICD, International Classification of Diseases; SMR, standardized mortality ratio; CI 95, 95% confidence interval; n, number of deaths.
The validity of physicians’ certificates on causes of death is satisfactory when diagnoses are grouped according to the major ICD classes. Long-term follow-up studies indicate that more than 95% of the patients had reversed hypercalcemia after the operation.

The mortality ratio relative to the general background population may not be applicable to the early postoperative period. The risk of death after surgery is a combination of the risk of death due to the illness per se and the risk associated with the operation. The perioperative mortality rate is higher than for other elective surgical procedures such as inguinal hernial repair, thyroidectomy or cataract operations. However, the pHPT group probably includes cases with non-cured malignant hypercalcemia and in some instances the indication for surgery can be classified as semielective. Mild hypercalcemia discovered in population-based screening has also been associated with excess cardiovascular mortality, albeit during a 25-year follow-up. In addition, the higher the calcium or parathyroid hormone levels, the higher the mortality risk.

Analysis of more than 15 000 Swedish pHPT patients with a single adenoma or multiglandular parathyroid disorder showed an increased mortality risk beyond the first postoperative year after PTx. The first postoperative year was omitted from these analyses to exclude mortality related to the operative procedure as such. The risk, which applied to both sexes and all age groups, persisted over 15 years after parathyroidectomy.

As could be expected from earlier reports, the dominant cause of death during the first month and first year after PTx was cardiovascular disease and the

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular</td>
<td>33</td>
<td>16</td>
<td>15</td>
<td>7</td>
</tr>
<tr>
<td>Tumor</td>
<td>17</td>
<td>2</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>Respiratory</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Endocrine</td>
<td>41</td>
<td>9</td>
<td>5</td>
<td>4</td>
</tr>
</tbody>
</table>

ICD, International Classification of Diseases; n, number of deaths.
risk estimates were similar for both genders and all ages. Several risk factors for the development of cardiovascular disorders are overrepresented in patients with pHPT (20). It may be assumed that the duration of disease is an important prognostic factor since the risk of dying is related to the degree of hypercalcemia and the weight of the parathyroid adenomas (18). Confounding by indication is a problem in studies of this kind and could explain the increased mortality rate related to tumor diagnoses, especially as pHPT is associated with an increased prevalence of some malignancies (21).

The aim of the present study was to analyze all cause mortality within 1 month and the following 11 months after PTx. Although PTx is usually regarded as a safe procedure, hypercalcemic crisis still carries a significant mortality, especially in patients with extremely high serum calcium levels (22, 23). Furthermore, conventional PTx under general anesthesia for high-risk pHPT has been associated, especially in elderly patients, with mortality and morbidity rates as high as 9%. In our country, more than 99% of PTx are performed under general anesthesia (24). The present study includes a total of almost 3000 pHPT patients who were over 75 years of age at the time of the operation. Although a selection bias may exist, we conclude that chronological age per se is no reason for abstaining from surgical treatment of pHPT. When deciding treatment of pHPT, the patient’s age should therefore be less important than other criteria.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This study was supported by grants from the Swedish Cancer Society, the Karolinska Institute and the Swedish Society of Medicine.

References

8 Coughtry S, Moulias S & Warril W. Primary hyperparathyroidism in the older person. Age and Ageing 2003 32 571–578.

Received 9 November 2008
Accepted 13 November 2008